Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 20/20 | 1.00 |
| ▸ | CHUK | O15111 | 16/20 | 1.00 |
| ▸ | CDK11B | P21127 | 2/20 | 1.00 |
| ▸ | CDK7 | P50613 | 2/20 | 1.00 |
| ▸ | CDK13 | Q14004 | 2/20 | 1.00 |
| ▸ | MAP3K19 | Q56UN5 | 2/20 | 1.00 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 1.00 |
| ▸ | CDK11A | Q9UQ88 | 2/20 | 1.00 |
| ▸ | ERN1 | O75460 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | TYK2 | P29597 | 1/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 1/20 | 1.00 |
| ▸ | CDK9 | P50750 | 1/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 1/20 | 1.00 |
| ▸ | CDK16 | Q00536 | 1/20 | 1.00 |
| ▸ | MAPK7 | Q13164 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bms-345541 SCHEMBL118886 | 1.00 | IKBKB (1.00) | IKBKBCHUKCDK11BCDK7CDK13 | |
| Bms-345541 SCHEMBL14141907 | 0.99 | IKBKB (1.00) | IKBKBCHUKCDK11BCDK7CDK13 | |
| Bms-345541 SCHEMBL30120667 | 0.99 | IKBKB (1.00) | IKBKBCHUKCDK11BCDK7CDK13 | |
| SCHEMBL25735941 | 0.89 | IKBKB (0.80) | IKBKBCHUKCDK11BCDK7CDK13 | |
| SCHEMBL17995389 | 0.77 | IKBKB (0.62) | IKBKBCHUKCDK11BCDK7CDK13 | |
| SCHEMBL20440096 | 0.76 | BRD4 (0.69) | IKBKBCHUKCDK11BCDK7CDK13 | |
| SCHEMBL14431616 | 0.76 | IKBKB (1.00) | IKBKBCHUKCDK11BCDK7CDK13 | |
| SCHEMBL18344276 | 0.74 | IKBKB (0.59) | IKBKBCHUKCDK11BCDK7CDK13 | |
| SCHEMBL31069482 | 0.74 | IKBKB (0.59) | IKBKBCHUKCDK11BCDK7CDK13 | |
| SCHEMBL14431694 | 0.74 | IKBKB (0.69) | IKBKBCHUKCDK11BCDK7CDK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4412621-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT Bio Corp. (US) | 2024-08-14 | — | — | EP | claimed |
| EP-3720493-B1 | COMBINATIONS OF RIPK1- AND IKK-INHIBITORS FOR THE PREVENTION OR TREATMENT OF IMMUNE DISEASES | UNIV KOELN (DE) | 2024-07-24 | — | — | EP | claimed |
| WO-2023150768-A2 | BIOMARKERS FOR ACUTE MYELOID LEUKEMIA AND USES THEREOF | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-08-10 | — | — | WO | claimed |
| WO-2023056202-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. (US) | 2023-04-06 | — | — | WO | claimed |
| CN-113174387-B | Hydrogel immobilized microorganism preservation method | 浙江海洋大学 | 2022-12-02 | — | — | CN | claimed |
| EP-3297613-B1 | MESOSCALE NANOPARTICLES FOR SELECTIVE TARGETING TO THE KIDNEY AND METHODS OF THEIR THERAPEUTIC USE | UNIV CITY NEW YORK RES FOUND (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4598633-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | The Brigham & Women's Hospital, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4598540-A1 | USE OF INHIBITORS OF THE HIPPO SIGNALLING PATHWAY FOR THE TREATMENT OF CHRONIC NEPHROPATHIES | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025128165-A2 | ELECTROPHILIC REACTIVE LINKERS FOR LABELING OF POLYPEPTIDES AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4433458-A2 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | The Broad Institute, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| EP-4412621-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT Bio Corp. (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-4106879-A1 | IDENTIFICATION OF AN EGFR-BIN3 PATHWAY THAT ACTIVELY SUPPRESSES INVASION AND REDUCES TUMOR SIZE IN GLIOBLASTOMA | United States Government as Represented by The Department of Veterans Affairs (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-4106793-A1 | EGFR INHIBITION TRIGGERS AN ADAPTIVE RESPONSE BY CO-OPTING ANTIVIRAL SIGNALING PATHWAYS IN LUNG CANCER | United States Government as Represented by The Department of Veterans Affairs (US) | 2022-12-28 | — | — | EP | disclosed |
| CN-113174387-B | Hydrogel immobilized microorganism preservation method | 浙江海洋大学 | 2022-12-02 | — | — | CN | disclosed |
| CN-113174387-B | Hydrogel immobilized microorganism preservation method | 浙江海洋大学 | 2022-12-02 | — | — | CN | disclosed |
| US-20220378046-A1 | EFFECTS OF NF-kB SIGNALING INHIBITORS ON BED BUG RESISTANCE TO ORALLY PROVISIONED ENTOMOPATHOGENIC BACTERIA | SOUTH DAKOTA BOARD OF REGENTS | 2022-12-01 | — | — | US | disclosed |
| US-11365229-B2 | Methods of treating neurological diseases | XENCOR, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| WO-2022120177-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378046-A1 | EFFECTS OF NF-kB SIGNALING INHIBITORS ON BED BUG RESISTANCE TO ORALLY PROVISIONED ENTOMOPATHOGENIC BACTERIA | NFKBIA, IKBKB, IKBKG | IKBKB 2/4885CHUK 7/4885CDK11B 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.